Description

Meronem IV (500mg) is presented as a sterile white powder containing meropenem 500 mg or 1g  as the trihydrate blended with anhydrous sodium carbonate for the constitution. Meronem IV injection contains 208 mg sodium carbonate for each gram of meropenem (anhydrous potency).
Vial for I.V. injection or infusion
Meronem 500 mg   1000 mg
Active ingredient:
Meropenem trihydrate                          570 mg         1140 mg
equivalent to anhydrous meropenem 500 mg         1000 mg
Excipient: Anhydrous sodium carbonate 104mg      208 mg
For each gram of meropenem (anhydrous potency), the vial contains 90 mg (3.9 mmol) of sodium.

Pharmaceutical form :

Powder for solution for intravenous injection or infusion.

Therapeutic indications :

Meronem IV is indicated for treatment, in adults and children, of the following infections caused by single or multiple bacteria sensitive to meropenem.
– Pneumonias and Nosocomial Pneumonias
– Urinary Tract Infections
– Intra-abdominal Infections
– Gynaecological Infections, such as endometritis and pelvic – inflammatory disease
– Skin and Skin Structure Infections
– Meningitis
– Septicaemia
– Empiric treatment, for presumed infections in adult patients with febrile neutropenia, used as monotherapy or in combination with anti-viral or anti-fungal agents.
Meronem has proved efficacious alone or in combination with other antimic bial agents in the treatment of polymicrobial infections.
There is no experience in paediatric patients with neutropenia or primary or secondary immunodeficiency.